Nuclear Cunts Part 2 Flashcards

0
Q

What is Chromosome Immunoprecipitation (ChIP) used for and how is it done?

A

Used for: mapping the DNA target of DNA-binding proteins and mapping the DNA target of histone modifying enzymes.
Method: Take a group of cells and cross-link the DNA and protein (or leave in its native bound form). Lyse the cells and then do sonication or enzyme digestion to fragment the chromatin Immunoprecipitate the DNA-protein complexes with antibodies directed towards the protein of interest. Purify the DNA and analyze the bound DNA using PCR, qPCR, Microarray, or sequencing.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

What are SERMS and what are they useful in treating?

A

SERMs are neither pure agonists nor pure antagonists. It depends on what tissue they are acting in. Useful for a variety of treatments, especially in cancer treatments.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How do structurally similar NR proteins regulate different genes in different cells?

A

Ligand:

  1. Different specificity for ligand binding by NR.
  2. Metabolic control of ligand availability (used to discriminate specificity between aldosterone and cortisol).
  • Nuclear Receptor:
    1. Recognize different DNA sequences (hormone response elements).
    2. Different expression patterns of NRs in cells (some may have higher levels of estrogen receptors than others, and so they respond differently to the ligands).
    3. Activate different coactivators/ coregulators . So the type of effect we get from the cell depends not only on the presence of the receptor, but also the assemblage of the coregulators that are also involved
    in regulating DNA.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Does ligand specificity always explain receptor specificity?

A

Nope. In some cases it doesn’t. Worst case scenario is comparing MR and GR. The affinity of mineralocorticoid receptor is almost the same for both cortisol and aldosterone. Similarly, looking at the glucocorticoid receptor, it also has similar affinities for cortisol and aldosterone. So how does the cell discriminate and respond appropriately to the ligand. For the glucocorticoid its pretty easy because cortisol is in a high abundance in the body compared to aldosterone, so the glucocorticoid receptor can stand for being regulated by aldosterone. And so the main regulator for the glucocorticoid receptor is cortisol just because of its high
abundance in the body (its about 10 times higher). This creates a problem for the mineralocorticoid receptor.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How does the mineralocorticoid receptor distinguish between cortisol and aldosterone if they have similar affinities for the receptors and cortisol is at a much higher concentration?

A

The cells in the collecting duct of the kidney have an enzyme that selectively degrades cortisol. This allows the mineralocorticoid receptor to just respond toaldosterone. This enzyme is 11 beta hydroxysteroid dehydrogenase. Located fairly exclusively in the colellcting duct, and selectively degrades cortisol so that it is no longer recognized by the mineralocorticoid receptor. So the specificity doesn’t stem from the ligand (ligand specificity), and doesn’t stem from the ligandbinding to the receptor (receptor specificity). It comes from the availability of the ligand because the ligand not being used is degraded. Converts cortisol to cortisone (inactive).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How can you study nuclear receptor function?

A

If you have the coding region of a receptor, transfect the plasmid into the cell. At the same time transfect another plasmid that may have a response element you want to test and evaluate for its activation or inhibition of transcription via action with the transfected nuclear receptor. Downstream of the element put a reporter gene. Typically luciferase. If the ligand binds then it allows for the transcription of luciferase which can be measured using a luminometer. Could also use Chloramphenicol Acetyl Transferase reporter gene to measure acetylation of chloramphenicol but this is an older and more difficult assay.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the functional domains of nuclear receptors?

A

N-terminus AF1 Co-activator region (isoform specific): This region is variable between receptors. Called AF-1 for Activator Functions.

  • DNA binding domain with “zinc fingers’: small region (about 62 aa) that binds to the response element.
  • Ligand binding domain (hormone binding domain): Hormone domain not only binds ligand to activate the nuclear receptor, but also has the co-activator binding region to, and thats the region thats going to be binding the histone acetyltransferase in the presence of ligand, or the histone deacetylase in the absence of ligand. Also binds HSP90 in the absence of receptor to inhibit the receptor action when ligand is not present and keep it in the cytosol.
  • Also usually a hinge region in between DNA binding domain and ligand binding domain.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Could one swap out different regions of nuclear receptor domains easily?

A

Yes. The receptors are very modular in domain. So one could take a glucocorticoid
receptor and swap out a region (maybe the ligand binding domain) for another
receptor (estrogen receptor) and you can switch its specificity very easily. So the
domains are very separate from one another and can be switched. Can do the same
with the DNA binding domain.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the homology of nuclear receptors.

A

The two classes have the same types of domains, but the receptors within a class are more similar to eachother than they are to receptors of a different class. So class I is like andother class I receptor and same goes with class II.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What do the DNA-binding domains of nuclear receptors look like and how do they bind DNA?

A

DNA binding domaine has cystein-cystein zinc fingers. Two sets of cysteins on each finger that coordinate the zinc ion that forms the finger. These regions bind DNA. It was thought that these fingers stuck down into the DNA, but this is not true. Instead, the first zinc finger asssumes a structure in which this part of the zinc finger forms an alpha helix and sits in the major groove of DNA and reads the nucleotides. The second zinc finger does not bind DNA at all, but is involved in dimerization between the two sets of zinc fingers in the two subunits of the homodimer. In general, proteins that bind DNA have some sort of a zinc finger. In the nuclear receptors, there are always 2 zinc fingers on each of the monomeric regions, but in proteins like transcription factors there can be more.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the important region in the ligand binding domain of nuclear receptors?

A

Helix 12 region on the C terminal end. Upon receptor binding, helix 12 changes its conformation and moves to another location. Agonist binds in a hydrophobic pocket which moves helix 12 in such a way to allow co-activators to bind to the receptor. Co-activators can then recruit enzymes such as HATs which acetylate the histones and allow for access of transcription factors and RNA pol. When antagonist binds helix 12 moves in such a way that blocks co-activators from binding and instead allows for co-repressors to bind. Histone deacetylases can then bind to the nuclear receptor and work to deacetylate the histones resulting in a tighter interaction between DNA and histones and tightens the winding of nucleosomes to repress transcription.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Do nuclear receptors only have the agonist bound state or antagonist bound states?

A

No. Not only can nuclear receptors transition between a state that favors co- activators and another state that favors co-repressors, but they can actually undergo intermediate transitions depending on the ligand thats bound. Selective receptor modulators dont put the receptors in a stricly agonist or antagonist state, but they put it in an intermediate state. So you can have different effects depending on the nature of the ligand.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are some effects of estrogen?

A

Estrogen has a lot of different effects on the body depending on age and maturity of the individual. In young individuals its involved in stimulating growth and female characteristics. As the individual ages it will be involved in stimulating reproductive function like ovulation and menstration. LH and FSH stimulate estrogen and progesterone production in ovaries. Reproductive function: ovulation, menstrual cycle, pregnancy. Development of female characteristics in puberty. Bone health, prevention of osteoporosis. Increase amount of “good” HDL cholesterol; decrease “bad” LDL cholesterol; decrease risk of heart disease, Estrogen-dependent cancers (breast, ovarian); cell proliferation, Thrombosis (blood clots), Prevent menopausal symptoms (hot flashes, mood swings, fatigue)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How does estrogen plus progesterone do as a hormone replacement therapy? What are some of the effects?

A
  • Estrogen given by itself was found to increase breast cancers, so they tried to give it with progesterone, but there were still some bad effects accompanying the good effects. The bad effects tended to outweigh the bad effects. Good effects: strengthens bones, decreases risk of colon cancer, reduces menopausal symptoms (hot flashes). Bad effects: increases invasive breast cancer risk, increases heart attacks, increases strokes, increases blood clots. The hormone replacement therapy was called Prempro. Because of these effects, women are much less often prescribed estrogen replacement meds, and if they are its for a much shorter time.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the main nautral agonist to estrogen receptors, what is it used as, and why is there interest to target the estrogen receptor?

A

Estrogen. Used as a contraceptive, typically combined with progesterone. Can also establish an ovulation cycle in women who don’t have one. Used as hormone replacement therapy. 80% of breast cancers have estrogen receptors on them and are responsive to estrogen. So one might want to inhibit the estrogen receptor.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are SERMS.

A
  • Partial agonists/ antagonists depending on the tissues they are acting in. Work on the estrogen receptor.
16
Q

Clomiphene

A

SERM used in infertitility treatment; blocks estrogen binding in the anterior pituitarty, leads to increased GnRH and stimulates ovulation. When treating infertility, one wants to increase estrogen levels. Want to inhibit negative feedback of hypothalamus and anterior pituitary. Blocks estrogen in the anterior pituitary but not in the body to stimulate ovulation. Antagonist in one region, but not the ovaries.

17
Q

Tamoxifen

A

Tamoxifen: Used to treat estrogen-dependent breast cancer. Used as an adjuvant therapy after surgery or radiation therapy. Antagonist of estrogen receptors in the breasts, so after surgery its useful for decreasing the resurgence of breast cancer. Has also been found to be effective when used as a preventative measure against breast cancer in terms of new occurrences. Good effects: lowers LDL cholesterol, reduces breast cancer risk, strengthens bones. Bad effects: increases uterine cancer risk, also increases blood clots.

18
Q

Raloxifene

A

Raloxifene: second generation drug of tamoxifen. Used to treat estrogen-dependent breast cancer as well as uterine cancer. Also used to treat osteoporosis for post-menopausal women. Also used as an adjuvant therapy after surgery or radiation therapy.

19
Q

Fulvestrant

A

Fulvestrant: Estrogen receptor antagonist. Typically used in aggressive breast cancers. There are a lot of negative side effects associated with pure estrogen receptor antagonists. Used to trat metastatic estrogen-dependent breast cancer, also increases the proteosomal degradation of estrogen receptor and so its also considered to be a downregulator of the estrogen receptor.

20
Q

Which types of drugs influence the synthesis of estrogen?

A

: aromatase inhibitors: block the synthesis of estrogen in post-menopausal women and are used in the treatment of: breast cancer as well as ovarian cancer in post menopausal women.

21
Q

How is estrogen tied with cancer and what are some treatment strategies?

A

: Cells are stimulated by estrogen. When cells DNA becomes damaged and estrogen causes proliferation, it increases the cancerous cells. So inhibiting the estrogen receptor in these cells might inhibit the estrogen-dependent breast cancers. Breast cancer is treated in a variety of ways: one is surgery to remove the breast cancer. Another is radiation therapy. There are often adjuvant therapies to treat after the cancer hasbeen removed to try and prevent the reoccurrence of cancer. The latter is where drugs come in to play. Sometimes cytotoxic drugs are used which are general proliferation-inhibiting drugs. But since many breast cancers are hormone-dependent, many of the drugs used target the estrogen receptor to try and inhibit it. SERMs sometimes can inhibit breast cancers but still have some positive effects on the body. One of these drugs is tomoxifen.

22
Q

What are aromatase inhibitors, and who are they given to?

A

: Estradiol is produced in ovaries, adrenal cortex (downstream of DHEA), adipose tissue, liver, brain, placenta. Aromatase enzyme converts androgens to estrogens in peripheral tissues (e.g. breasts). Aromatase inhibitors block estrogen production in post-menopausal women, where major source of estrogen is the adrenal cortex. Aromatase inhibitors are not generally used in premenopausal women, because ints effects are reduced by hypothalamus/ pituitary feedback: decreased estrogen leads to increased GnRH, giving increased levels of LH and FSH, resulting in increased levels of estrogen. So the feedback mechanism in pre-menopausal women is too strong and will re-up the estrogen levels.

23
Q

How do antiestrogens work?:

A

Normally estrogen will enter the cell, bind to the estrogen receptor, both will bind to DNA and recruit coactivators, resulting in the activation of target genes. With an antiestrogen, it binds to the receptor, binds to DNA but the coactivators are not able to bind, so no gene transcription results.

24
Q

What are selective receptor modulators (SRMs), who are they typically given to, give an example of a few

A

. : partial agonists/ antagonist whose action depends on the ligand and the target tissue. Usually given to premenopausal women. SERMs: estrogen receptor: used for protection of bones and as anti-cancer agents. SPRMs: progesterone receptor: under investigation for endometriosis and uterine fibroid tumors. SARMs: androgen receptor: want to develop these drugs to protect bones and promote muscle without side effects. SGCRM: glucocorticoid receptor: want to develop drugs for anti-inflammatory purposes with fewer side effects.

25
Q

What would the ideal SERM do?

A

Stengthen bones, lower LDL cholesterol and raise HDL cholesterol, not increase blood clot risk, relieve hot flashes, reduce breast cancer risk, reduce uterine cancer risk.

26
Q

How can SERMs have different effects on different tissues?

A

: 1. Different estrogen receptors: there are two estrogen receptors :ER alpha and ER beta. They are both widely distributed but with some selectivity for particular tissues. Different SERMs may interact selectively with different ERs. (these probably aren’t responsible for the agonist effects in some tissues and antagonist effects in others). 2. ERs may adopt multiple conformations, depending on the ligand, and recruit different co-activators or co-repressors. A combination of multiple ER conformations with different tissues distribution of co-activators and co-repressors may be the underlying reason. (This is more likely to be the cause of the different activities in different tissues). 3. Different distribution and abundance of co-activators and co-repressors in different tissues. (this may also play a role).

27
Q

What is the model for SERM binding and what effect do concentrations of co-regulators play?

A

: SERM-bound ER-ligang domains take on an intermediate structure. Difference in cofactor binding on these ligand bound domains gives them distinct preferences of coregulator partners. The relative concentration of coactivator/ corepressor may determine SERM-bound ER’s action. Model proposes that SERMs enable ER to bind to multiple types of coregulators.